Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Save Sight Now To Reduce Costs Later
Eye disease and sight loss cost the UK nearly ÷£6.5bn in 2008, according to new research** which informs, "Cost Oversight", a report due later this summer from the Royal National Institute of Blind People (RNIB). In addition, research found that the impact on quality of life (including loss of healthy life and premature death) associated with partial sight and blindness also has a cost to society, estimated at a further ÷£15.5bn in 2008.
pharmacy online
New Data Shows Requip-Modutab Improves Nocturnal Symptoms In Patients With Advanced Parkinson's Disease
New data presented at the 13th International Congress of Parkinson"s Disease and Movement Disorders show that Requip-Modutab* (ropinirole prolonged release tablets) improves nocturnal symptoms experienced by patients with advanced Parkinson"s disease (PD).[i] The data showed that patients with more significant nocturnal symptoms had a greater improvement with Requip-Modutab, when used as an adjunct to levodopa (L-dopa), versus placebo. These data indicate that once-daily Requip-Modutab remains effective in treating PD symptoms over the night as well as during the day and provides benefit to those in most need. Sleep disturbances, a key element of nocturnal symptoms, are one of the most common non-motor complications of PD and can affect up to 98% of patients.[ii]
News of the day
Head Movement Is More Important Than Gender In Nonverbal Communication, Psychologists Find
It is well known that people use head motion during conversation to convey a range of meanings and emotions, and that women use more active head motion when conversing with each other than men use when they talk with each other.
Public Health

ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced that it presented final data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd. The Phase I trial of palifosfamide in combination with doxorubicin was fully enrolled with 13 patients, predominantly with soft tissue sarcoma and non-small cell lung cancer, and who had received a median of two prior therapies. Of 12 evaluable patients, there were 3 partial responses. Of the 8 patients with soft tissue sarcoma (STS) 75 percent had stable disease or better, with 2 having partial responses and 4 having prolonged stable disease. The median progression free survival (PFS) was 19 weeks. The combination has proven to be easily administered and was well tolerated with no dose-limiting toxicities during a total of 73 cycles of treatment. Importantly, there were no reported events of encephalopathy, hemorrhagic cystitis or renal toxicity often associated with some current treatments for STS. Adverse events were primarily hematologic, including neutropenia and thrombocytopenia, and were managed easily. The pharmacokinetic evaluation in this trial indicates that palifosfamide exposure is comparable to that seen in murine models that resulted in marked synergy with doxorubicin. The Company is now enrolling into a Phase II randomized controlled trial comparing palifosfamide plus doxorubicin vs. doxorubicin in the front- and second-line treatment setting of STS. This is a multicenter, multinational trial in the United States and Europe. The objective of the randomized Phase II trial is to validate certain hypotheses that would form the basis for a registration trial to be initiated as early as the first half of next year. "These highly favorable Phase I data of palifosfamide in combination with doxorubicin established the foundation for the now ongoing Phase II randomized trial in the front and second-line setting", commented Sant Chawla, MD, co-principal investigator. "Data has previously been reported on the activity of palifosfamide as a single agent in advanced sarcoma as well as the established synergy of palifosfamide with doxorubicin preclinically. With so few treatment options, I look forward to ZIOPHARM initiating the final phase of the drug development program that could establish the first new front-line sarcoma therapy in decades and as well to advancing into the clinic an oral form for much expanded patient access." To view the presentation please visit here. ZIOPHARM Oncology, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009